Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Clinical Effects of Lactobacillus reuteri on Gingival Inflammation and Alveolar Bone Loss in Periodontitis.

  • 2025-09-30
  • Oral health & preventive dentistry 23
    • Jian Lu
    • Xiaoxiang He
    • Ting Du
    • Dongjie Fu

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 120
Population
120 patients (aged 22-47 years) with periodontitis (n = 84) or gingivitis (n = 36)
Methods
Randomized, double-blind, placebo-controlled trial; 8 weeks of L. reuteri 1×10⁹ CFU/day or placebo
Blinding
Double-blind
Duration
8 weeks
  • Large Human Trial

Purpose

This randomized, double-blind, placebo-controlled trial evaluated the clinical efficacy of Lactobacillus reuteri in reducing gingival inflammation and alveolar bone loss in periodontitis by modulating endoplasmic reticulum (ER) stress.

Materials and methods

A total of 120 patients (aged 22-47 years) with periodontitis (n = 84) or gingivitis (n = 36) were allocated to receive either L. reuteri (1×10⁹ CFU/day, n = 60) or placebo (n = 60) for 8 weeks. Primary outcomes included ER stress markers (GRP78/CHOP), while secondary outcomes comprised probing depth (PD), clinical attachment level (CAL), inflammatory biomarkers (TNF-α, IL-6, CRP), and radiographic alveolar bone loss (Moffat grading). Statistical analyses utilized ANOVA, Welch's t-test, and ANCOVA, with significance at p 0.05.

Results

The L. reuteri group exhibited statistically significant reductions in TNF-α (30.01 ± 5.15 vs 16.57 ± 3.88 pg/ml, -45.3%, p 0.05), IL-6 (25.84 ± 3.11 vs 14.35 ± 2.16 pg/ml, -45.2%, p 0.05), and CRP (6.41 ± 1.18 vs 2.68 ± 1.04 mg/L, -57.8%, p 0.05) compared to placebo. Gingival pain (VAS) decreased by 48.5% (5.22 ± 0.51 to 2.69 ± 0.20, p 0.001). ER stress markers GRP78 and CHOP declined by 37.6% (p 0.01) and 35.2% (p 0.01), respectively. PD improved by 35.8% (4.92 ± 1.13 vs 3.12 ± 0.37 mm, p 0.05), with 68.3% of patients achieving ≥2 mm PD reduction (vs 13.3% in controls, p 0.001). Radiographic bone loss improved to mild Moffat grades in 66.7% of test patients (vs 33.3% in controls, p 0.001).

Conclusions

L. reuteri statistically significantly alleviates periodontitis by inhibiting ER stress and inflammatory pathways, demonstrating clinically meaningful reductions in PD, CAL, and alveolar bone loss. These findings underscore its therapeutic potential as an adjunctive intervention.

Research Insights

Back to top